Characteristics of New Biologic Users Among the Moderate-to-Severe Psoriasis Population—Retrospective Cohort Study Leveraging the Modernizing Medicine Data Services Database

INTRODUCTION: Biologics have expanded the treatment options in the management of patients with moderate-to-severe psoriasis. The objective of this study was to describe patient characteristics and previous treatments in psoriasis patients newly treated with guselkumab, secukinumab, or ixekizumab. ME...

Descripción completa

Detalles Bibliográficos
Autores principales: Fitzgerald, Timothy, Near, Aimee M., Kim, Hyunchung, Teeple, Amanda, Olurinde, Mobolaji, Rowland, Katelyn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8941060/
https://www.ncbi.nlm.nih.gov/pubmed/35212934
http://dx.doi.org/10.1007/s13555-022-00691-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8941060/
https://www.ncbi.nlm.nih.gov/pubmed/35212934
http://dx.doi.org/10.1007/s13555-022-00691-4

Ejemplares similares